BITTE BEACHTEN
Für den Erwerb der NCH421K Zelllinie müssen bestimmte Voraussetzungen erfüllt sein:
Nur gemeinnützige Institutionen k?nnen diese Zelllinien erwerben.
Ein MTA muss unterzeichnet werden.
Ohne ein unterzeichnetes Bestellformular der CLS Cell Lines Service GmbH kann kein Versand erfolgen.
| Designation: | NCH421K | | Depositor: | C. Herold-Mende | | Organism: | Homo sapiens (human) | | Ethnicity: | Caucasian | | Age/Stage: | 66 years of age | | Gender: | Male | | Tissue: | Brain | | Morphology: | Spheroid culture | | Celltype: | Glioma / Glioblastoma WHO IV | | Growth Properties: | Cluster in suspension | | Description: | The NCH421K cell line was established by Christel Herold-Mende in 2008. | | Culture Medium: | Chemically defined serum-free media. CLS order no. 820403. | | Subculturing: | Mechanical dissociation: Pipette 5-10 times using an Eppendorf pipette and 1000μl tips after centrifuging the cells 10min at 300xg at +20°C. | | Split Ratio: | An initial ratio of 1:2 to 1:5 is recommended according to the growth rate. | | Fluid Renewal: | 2 times weekly | | Freeze Medium: | CM-2, serumfree Cryoprotective medium (CLS order no. 800225 or 800250) | | Sterility: | Test for mycoplasma: PCR tested negative.
Test for bacteria: PCR tested negative. | | Biosafety Level: | 1 | | Tumorigenic: | Yes | | DNA Profile (STR): | Amelogenin: X,Y
CSF1PO: 10,11
D13S317: 8,11
D16S539: 10,11
D5S818: 11,13
D7S820: 10,12
THO1: 6
TPOX: 8,11
vWA: 17,18
D3S1358: 14,16
D21S11: 30
D18S51: 13
Penta E: 7,12
Penta D: 9,13
D8S1179: 12,15
FGA: 21,25
CLS Cell Lines Service GmbH, 2012.
| | Immunology: | NCH421K are highly CD133 positive. |
References:
Campos B. et al. Differentiation Therapy Exerts Antitumor Effexts on Stem-like Glioma Cells. Clin Cancer Res. 16(10): 2715--28, 2010.
Ernst A., Homann S. Ahmadi R. et al. Genomic and Expression Profiling of Glioblastoma Stem Cell-Like Spheroid Cultures Identifies Novel Tumor-Relevant Genes Associated with Survival. Clin Cancer Res. 15: 6541-6550, 2009. |
|
|